← Russell 3000 cross-section

OPRX OptimizeRx Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Technology

Scale

Market cap
$147m
Revenue TTM
$99m
Net income TTM
$5m
Free cash flow
$18m
Composite score
65.7
Sector rank
#2975

Valuation

P / E
31.9
EV / EBITDA
EV / sales
1.4
FCF yield
12.50%
Earnings yield vs 10-yr
-1.60pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
4.7%
EBITDA margin
ROE
3.5%
ROIC
8.8%
Revenue growth
-5.8%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our strategy for driving revenue growth is also expected to work in tandem with our efforts to increase margin and profitability as revenue drivers such as DAAP have inherently higher margins than most other messaging solutions we offer. In addition, by aiming to transition our DAAP customers to a more predictable subscription-based model for data services, we believe will further improve margins, increase visibility, and enhance the overall predictability of our revenue streams over time. Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively. …OptimizeRx Corp, 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →